Analysis of affordability differences for rare diseases in China: a comparison across disease types and regions

Ye Chen,Xinyang Chen,Yi Deng,Jinxi Ding

DOI: https://doi.org/10.1186/s12939-024-02137-z

2024-03-22

International Journal for Equity in Health

Abstract:China has implemented policies to make rare diseases more affordable. While previous studies evaluated overall affordability, few have examined affordability differences across regions and disease types. Given the vastness of China and varying medical policies across cities, this study assesses the affordability of rare diseases based on China's First List of Rare Diseases (CFLRD), National Reimbursement Drug List (NRDL), and outpatient chronic and special disease policies in each prefecture.

public, environmental & occupational health

What problem does this paper attempt to address?

The paper primarily explores the affordability issues of rare diseases in China and analyzes the differences between various disease types and regions.

### Research Background

China has implemented a series of policies to improve the affordability of rare disease treatments. However, previous studies have mostly focused on overall affordability, with less attention to the differences between regions and disease types. Given China's vast territory and the varying medical policies across cities, this study aims to assess the affordability of rare disease treatment costs based on China's first rare disease list (CFLRD), the National Reimbursement Drug List (NRDL), and outpatient chronic disease and special disease policies in various cities.

### Research Methods

1. **Disease Selection**: Six rare diseases were selected for the study, including hemophilia, Parkinson's disease (young-onset and early-onset), multiple sclerosis, systemic sclerosis, Niemann-Pick disease, and Fabry disease.
2. **Cost Calculation**: The average annual treatment costs of all drugs related to these diseases in the NRDL were calculated.
3. **Policy Coverage Analysis**: Using the standard method of the World Health Organization/Health Action International (WHO/HAI), the outpatient chronic disease and special disease policies in 289 cities were analyzed. The safety level of insurance was measured by the actual reimbursement ratio, and affordability was measured by the ratio of out-of-pocket expenses to the annual disposable income of urban residents.
4. **Statistical Analysis**: Mann-Whitney U test and Kruskal-Wallis H test were used to analyze the differences in affordability between different disease types and regions.

### Main Findings

1. **Affordability Differences**: The affordability of rare diseases is significantly affected by the type of disease and the annual treatment costs. For diseases with annual treatment costs below 100,000 RMB, patients in all regions can afford the treatment costs even with low reimbursement rates. However, for diseases with higher treatment costs, it is difficult to afford the costs in at least 80% of the regions, even with high reimbursement ratios.
2. **Regional Differences**: There are significant differences in the affordability of the same disease between different provinces and municipalities. The inconsistency between outpatient chronic disease and special disease insurance and major disease insurance leads to regional differences.
3. **Conclusion**: Although China has made some progress in improving the affordability of rare disease treatments, the differences between cities and diseases remain significant. The study suggests optimizing the basic medical insurance system and exploring independent funds and innovative insurance models to enhance the affordability of rare disease treatments, especially for those with extremely high treatment costs.

### Summary

This paper reveals the issues and causes of the affordability of rare disease treatment costs in China through detailed analysis and proposes corresponding improvement suggestions. This has important reference value for formulating more equitable and effective rare disease treatment policies.